Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Legionnaires' disease in Europe: all quiet on the eastern front?

Julien Beauté, Emmanuel Robesyn, Birgitta de Jong on behalf of the European Legionnaires' Disease Surveillance Network
European Respiratory Journal 2013 42: 1454-1458; DOI: 10.1183/09031936.00089113
Julien Beauté
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Julien.beaute@ecdc.europa.eu
Emmanuel Robesyn
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgitta de Jong
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Almost 40 years ago, a large outbreak of pneumonia caused by a previously unidentified agent occurred at a hotel in Philadelphia (PA, USA), affecting 182 persons and causing the death of 29 [1]. All cases had attended a convention of the American Legion, a US wartime veteran service organisation. Both the causative agent of the outbreak and the disease were named after this event: Legionella spp. and Legionnaires' disease, respectively. Legionella spp. are Gram-negative bacteria found in freshwater environments worldwide and tend to contaminate and thrive in man-made water systems [2]. Legionnaires' disease is not transmitted from person to person. Infection occurs following inhalation of aerosols containing Legionella or aspiration of Legionella contaminated water, most commonly Legionella pneumophila serogroup 1 [2, 3], but other Legionella species have been documented (table 1) [4]. Legionnaires' disease usually presents as a severe pneumonia that may be accompanied by systemic symptoms. Known risk factors for Legionnaires' disease include increasing age, male sex, smoking, chronic lung disease, diabetes and various conditions associated with immunodeficiency [5, 6]. Pontiac fever is a milder form of legionellosis, classically described as an influenza-like illness. Antibiotics with good intracellular action are most effective against any form of legionellosis. Azithromycin and levofloxacin are usually considered as the best first-line option [7, 8]. Mortality from Legionnaires' disease remains substantial (≈10%), even in patients who receive appropriate treatment [9]. A summary of the characteristics of Legionnaires' disease and Pontiac fever are presented in table 2.

View this table:
  • View inline
  • View popup
Table 1– Summary of agent, mechanism of transmission and risk factors
View this table:
  • View inline
  • View popup
Table 2– Main characteristics and treatment of Legionnaires' disease and Pontiac fever

Since the first description of Legionnaires' disease, much of the attention has focused on large outbreaks because of their dramatic public health impact. About 10 years ago, the largest outbreak ever reported affected 449 cases in Murcia, Spain [10]. A more recent outbreak in 2012 comprised 50 confirmed cases in Edinburgh, UK [11]. In these two outbreaks and many others, a cooling tower was incriminated as the probable source. High-risk sites (cooling towers, spas, cruising ships, etc.) should be regularly checked for Legionella. Appropriate control measures may prevent a significant number of cases [12, 13]. Although of major public health relevance, these large outbreaks tend to eclipse the sporadic cases which form the majority of cases of Legionnaires' disease [14].

Infectious disease surveillance is an import tool in detecting unusual events, assessing trends and monitoring the impact of programmes [15–23]. Legionnaires' disease is notifiable in all 27 European Union countries, plus Iceland and Norway. In 1996, Legionnaires' disease surveillance at the European level was initiated by a network of motivated epidemiologists and microbiologists. Since 2010, this network has operated under the name of European Legionnaires' Disease Surveillance Network (ELDSNet), coordinated by the European Centre for Disease Prevention and Control (ECDC) in Stockholm, Sweden. Two distinct Legionnaires' disease surveillance systems are currently in place. One is based on annual passive reporting of all Legionnaires' disease cases notified nationally, the other on the daily reporting of cases of travel-associated Legionnaires' disease (TALD). The latter scheme aims at identifying and containing clusters linked to stays in the same accommodation, which otherwise may not be detected at a national level. The success of the European TALD surveillance, as well as in triggering preventive measures in tourist accommodation, has now been well established, and each year nearly half of the clusters detected would have probably remained unnoticed without the network because the cases associated were reported by different countries [24, 25].

The surveillance of all Legionnaires' disease cases in Europe has provided interesting insights. First, after a period of steady increase at the European level, the number and rate of annually reported cases has plateaued or followed a slow increasing trend from 2005 to 2010 [14]. This may suggest that national surveillance schemes have reached their maximum detection capacity under current diagnostic conditions, at least in the countries reporting most cases (six countries accounted for ≈85% of all cases in 2011 [24]). One survey aimed at estimating the annual number of tests performed in each European country which could help understand why the majority of reported cases are concentrated in a few countries. Secondly, there are large differences in Legionnaires' disease notification rates between European Union countries (fig. 1), which cannot be fully explained by differences in local risk and seem to point to important disparities in awareness among clinicians, diagnostic capability or capacity, and reporting across countries. This is especially striking in eastern and south-eastern European countries where the numbers of cases reported are far below the European Union average of approximately 10 per million population [24–26]. In 2011, the notification rate of community-acquired Legionnaires' disease was below one per million in Bulgaria, the Czech Republic, Greece, Romania and Slovakia (fig. 1). A recent study using tourism patterns as denominators also suggested that under-ascertainment was substantial in Greece [27]. Thirdly, the disease's seasonality, with most cases reported during the warm season, is highly suggestive of an influence of environmental conditions on Legionnaires' disease incidence. This was already suggested by previous studies [28–30], even though the link between weather patterns and Legionnaires' disease incidence remains to be fully elicited. Finally, the urinary antigen test has now become by far the most used diagnostic test for Legionnaires' disease. Since this test only detects L. pneumophila serogroup 1, some cases due to other species may be missed. The reference method (culture) was used in only 12% of all cases reported in 2011 in Europe with substantial differences across countries [24].

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

2011 notification rates of community-acquired Legionnaires' disease, according to the European Union/European Economic Area (n = 2642). Countries with >25% of infection settings reported as unknown were not included.

These findings have important implications for both clinicians and public health professionals. First, clinicians should not consider Legionnaires' disease as an unusual, exotic disease. Prospective studies have suggested that L. pneumophila was the causative pathogen in 2% of outpatients, 5% of hospitalised patients and 8% of intensive care unit patients with community-acquired pneumonia (CAP) [31]. Secondly, Legionnaires' disease is not merely a disease affecting southern countries. High notification rates of community-acquired Legionnaires' disease have been observed in northern European countries, such as Denmark or Latvia (11 and 18 cases/million inhabitants in 2011, respectively [24]). Finally, if routine testing for Legionnaires' disease has not been recommended for all outpatients with CAP for reasons of cost-effectiveness [32], testing should be considered in any patient with unexplained pneumonia and risk factors for Legionnaires' disease and should probably be expanded during the warm season. Apart from a quicker and more effective antimicrobial choice, this will allow for a better detection and control of possible sources of new infections.

A better understanding of the risk for Legionnaires' disease would allow us to better target preventive measures and improve clinician awareness. Countries with unrealistically low notification rates may need support in identifying and addressing local causes of under ascertainment, but also in improving prevention and control of the disease. Due to this, the ECDC organises annual Legionnaires' disease training courses for public health experts in the field of epidemiology, microbiology and environmental health. However, clinical societies, such as the European Respiratory Society, are much better placed to increase awareness among clinicians, be it through education and training, or through promotion of local studies (e.g. cross-sectional studies at major university hospitals in countries with very low notification rates). A close collaboration between public health, clinicians and microbiologists is of utmost importance for further improving the surveillance and consequently the prevention of Legionnaires' disease and its high morbidity and mortality.

Footnotes

  • Conflict of interest: None declared.

  • Received May 24, 2013.
  • Accepted June 28, 2013.
  • ©ERS 2013

References

  1. ↵
    1. Fraser DW,
    2. Tsai TR,
    3. Orenstein W,
    4. et al
    . Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297: 1189–1197.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Fields BS,
    2. Benson RF,
    3. Besser RE
    . Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002; 15: 506–526.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Carratalà J,
    2. Garcia-Vidal C
    . An update on Legionella. Curr Opin Infect Dis 2010; 23: 152–157.
    OpenUrlCrossRefPubMed
  4. ↵
    1. De Jong B,
    2. Zucs P
    . Legionella, springtime and potting soils. Euro Surveill 2010; 15: 19497.
    OpenUrlPubMed
  5. ↵
    1. Marston BJ,
    2. Lipman HB,
    3. Breiman RF
    . Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med 1994; 154: 2417–2422.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Ginevra C,
    2. Duclos A,
    3. Vanhems P,
    4. et al
    . Host-related risk factors and clinical features of community-acquired Legionnaires disease due to the Paris and Lorraine endemic strains, 1998–2007, France. Clin Infect Dis 2009; 49: 184–191.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Woodhead M,
    2. Blasi F,
    3. Ewig S,
    4. et al
    . Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011; 17: Suppl. 6, E1–E59.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Pedro-Botet ML,
    2. Yu VL
    . Treatment strategies for Legionella infection. Expert Opin Pharmacother 2009; 10: 1109–1121.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Chidiac C,
    2. Che D,
    3. Pires-Cronenberger S,
    4. et al
    . Factors associated with hospital mortality in community-acquired legionellosis in France. Eur Respir J 2012; 39: 963–970.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. García-Fulgueiras A,
    2. Navarro C,
    3. Fenoll D,
    4. et al
    . Legionnaires' disease outbreak in Murcia, Spain. Emerging Infect Dis 2003; 9: 915–921.
    OpenUrlPubMedWeb of Science
  11. ↵
    1. McCormick D,
    2. Thorn S,
    3. Milne D,
    4. et al
    . Public health response to an outbreak of Legionnaires' disease in Edinburgh, United Kingdom, June 2012. Euro Surveill 2012; 17: 20216.
    OpenUrlPubMed
  12. ↵
    1. Chartier Y,
    2. Lee JV,
    3. Pond K,
    4. et al
    . eds. Legionella and the Prevention of Legionellosis. Geneva, World Health Organization, 2007.
  13. ↵
    1. Azara A,
    2. Piana A,
    3. Sotgiu G,
    4. et al
    . Prevalence study of Legionella spp. contamination in ferries and cruise ships. BMC Public Health 2006; 6: 100.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Beauté J,
    2. Zucs P,
    3. de Jong B
    . Legionnaires' disease in Europe, 2009–2010. Euro Surveill 2013; 18: 20417.
    OpenUrlPubMed
  15. ↵
    1. Zignol M,
    2. Sismanidis C,
    3. Falzon D,
    4. et al
    . Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2013; 42: 701–707.
    OpenUrlAbstract/FREE Full Text
    1. Van Hest R,
    2. Kodmon C,
    3. Verver S,
    4. et al
    . Tuberculosis treatment outcome monitoring in European Union countries: systematic review. Eur Respir J 2012; 41: 635–643.
    OpenUrlPubMedWeb of Science
    1. Van der Werf MJ,
    2. Blasi F,
    3. Giesecke J,
    4. et al
    . Lessons learnt in Europe on tuberculosis surveillance, outbreaks and BCG vaccination in 2011. Eur Respir J 2013; 41: 767–771.
    OpenUrlFREE Full Text
    1. Pontali E,
    2. Pasticci MB,
    3. Matteelli A,
    4. et al
    . Tuberculosis and HIV co-infection: do we have a surveillance system in Europe? Eur Respir J 2011; 38: 1258–1260.
    OpenUrlFREE Full Text
    1. Pimpin L,
    2. Drumright LN,
    3. Kruijshaar ME,
    4. et al
    . Tuberculosis and HIV co-infection in European Union and European Economic Area countries. Eur Respir J 2011; 38: 1382–1392.
    OpenUrlAbstract/FREE Full Text
    1. Migliori GB,
    2. Zellweger JP,
    3. Abubakar I,
    4. et al
    . European Union standards for tuberculosis Care. Eur Respir J 2012; 39: 807–819.
    OpenUrlAbstract/FREE Full Text
    1. Migliori GB,
    2. Sotgiu G,
    3. D'Ambrosio L,
    4. et al
    . TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619–625.
    OpenUrlAbstract/FREE Full Text
    1. Kruijshaar ME,
    2. Pimpin L,
    3. Abubakar I,
    4. et al
    . The burden of TB-HIV in the EU: how much do we know? A survey of surveillance practices and results. Eur Respir J 2011; 38: 1374–1381.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Jenkins HE,
    2. Plesca V,
    3. Ciobanu A,
    4. et al
    . Assessing spatial heterogeneity of MDR-TB in a high burden country. Eur Respir J 2012 [in press DOI: 10.1183/09031936.00111812].
  17. ↵
    European Centre for Disease Prevention and Control. Legionnaires' disease surveillance in Europe, 2011. Stockholm, ECDC, 2013.
  18. ↵
    European Centre for Disease Prevention and Control. Legionnaires' disease surveillance in Europe, 2010. Stockholm, ECDC, 2012.
  19. ↵
    European Centre for Disease Prevention and Control. Legionnaires' disease surveillance in Europe, 2009. Stockholm, ECDC, 2011.
  20. ↵
    1. Beauté J,
    2. Zucs P,
    3. de Jong B
    . Risk for travel-associated Legionnaires' Disease, Europe, 2009. Emerg Infect Dis 2012; 18: 1811–1816.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Ricketts KD,
    2. Charlett A,
    3. Gelb D,
    4. et al
    . Weather patterns and Legionnaires' disease: a meteorological study. Epidemiol Infect 2009; 137: 1003–1012.
    OpenUrlCrossRefPubMedWeb of Science
    1. Hicks LA,
    2. Rose CE Jr.,
    3. Fields BS,
    4. et al
    . Increased rainfall is associated with increased risk for legionellosis. Epidemiol Infect 2007; 135: 811–817.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Fisman DN,
    2. Lim S,
    3. Wellenius GA,
    4. et al
    . It's not the heat, it's the humidity: wet weather increases legionellosis risk in the greater Philadelphia metropolitan area. J Infect Dis 2005; 192: 2066–2073.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Woodhead M
    . Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J 2002; 20: Suppl. 36, 20s–27s.
    OpenUrlCrossRefWeb of Science
  24. ↵
    1. File TM
    . Community-acquired pneumonia. Lancet 2003; 362: 1991–2001.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 42 Issue 6 Table of Contents
European Respiratory Journal: 42 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Legionnaires' disease in Europe: all quiet on the eastern front?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Legionnaires' disease in Europe: all quiet on the eastern front?
Julien Beauté, Emmanuel Robesyn, Birgitta de Jong
European Respiratory Journal Dec 2013, 42 (6) 1454-1458; DOI: 10.1183/09031936.00089113

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Legionnaires' disease in Europe: all quiet on the eastern front?
Julien Beauté, Emmanuel Robesyn, Birgitta de Jong
European Respiratory Journal Dec 2013, 42 (6) 1454-1458; DOI: 10.1183/09031936.00089113
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Commemorating World Tuberculosis Day 2022
  • Is low level of vitamin D a marker of poor health or its cause?
  • Hypertension in OSA: predicting BP reduction under CPAP
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society